Titles
- Cross labeling oncology drugs in combination regimens: guidance for industry1
- Current good manufacturing practice and preventive controls, foreign supplier verification programs, intentional adulteration, and produce safety regulations: enforcement policy regarding certain provisions1
- Data elements for research on the role of social determinants of health in Coronavirus disease 2019: infection and outcomes in the U.S1
- Defense health agency: oversight needed to better ensure that children are screened, tested, and treated for lead exposure : report to congressional committees1
- Defense health care: Actions needed to improve billing and collection of debt for civilian emergency care : report to congressional committees1
- Defense health care: DOD expects new IT system capabilities to improve other health insurance processing : report to congressional committees1
- Defense health care: Prevalence of and efforts to screen and treat mental health conditions in prenatal and postpartum TRICARE beneficiaries : report to congressional committees1
- Delays in confirmatory trials for drug applications granted FDA’s accelerated approval raise concerns1
- Demographic characteristics of adults receiving COVID-19 booster vaccinations1
- Denture base resins: performance criteria for safety and performance based pathway : guidance for industry and Food and Drug Administration Staff1
- Doula care and maternal health: an evidence review1
- Drug product tracing: the effect of section 585 of the FD&C Act : questions and answers1
- Drug products, including biological products, that contain nanomaterials1
- Drug safety: FDA should take additional steps to improve its foreign inspection program : report to congressional requesters1
- During the initial COVID-19 response, HHS personnel who interacted with potentially infected passengers had limited protections1
- E14 and S7B clinical and nonclinical evaluation of QT/QTc interval prolongation and proarrhythmic potential: questions and answers1
- E19: a selective approach to safety data collection in specific late-stage preapproval or post-approval clinical trials : guidance for industry1
- E2B(R3) electronic transmission of Individual Case Safety Reports (ICSRs) implementation guide: data elements and message specification1
- E8(R1) general considerations for clinical studies1
- Early changes in waivered clinicians and utilization of buprenorphine for opioid use disorder after implementation of the 2021 HHS Buprenorphine Practice Guidelines1